<DOC>
	<DOCNO>NCT02780609</DOCNO>
	<brief_summary>Phase I : The primary purpose study phase determine best dose also refer maximum tolerate dose ( MTD ) Selinexor use combination high-dose melphalan condition regimen hematopoietic cell transplant . Phase II : The primary purpose study phase assess complete response ( CR ) conversion rate .</brief_summary>
	<brief_title>Selinexor Plus High-Dose Melphalan ( HDM ) Before Autologous Hematopoietic Cell Transplantation Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>18 year age old histologically confirm multiple myeloma Achieving partial response ( PR ) good partial response ( VGPR ) systemic chemotherapy Received le 3 line antimyeloma therapy . Karnofsky performance status &gt; = 70 % Adequate pulmonary , cardiac , hepatic renal function outline protocol Signed informed consent form accordance institutional policy prior initiation highdose therapy Nonsecretory multiple myeloma Have achieve complete response ( CR ) prior autologous hematopoietic cell transplantation ( HCT ) Central nervous system ( CNS ) involvement Uncontrolled bacterial , viral fungal infection Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior malignancy within last 5 year except resect basal cell carcinoma treat cervical carcinoma situ . Females pregnant breastfeeding Have receive investigational drug within 14 day prior screen Prior autologous allogeneic HCT Prior organ transplant autoimmune disease require immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>autologous hematopoietic cell transplantation ( HCT )</keyword>
	<keyword>high-dose melphalan</keyword>
	<keyword>selinexor</keyword>
</DOC>